The overall goals of the Gastrointestinal Cancer Program (GICP) are to identify and characterize the underlying molecular mechanisms responsible for the neoplastic transformation of lymphomas, validate the components of these mechanisms as biomarkers for diagnosis, prognosis and therapeutic intervention, and develop new therapies for lymphomas using novel inhibitors which target the specific oncogenic changes identified in different subsets of lymphomas. The program is organized along three major themes:
- Molecular Diagnosis and Target Discovery - Use of genome-wide investigations to improve diagnosis, assess prognosis, and develop new therapies for patients with lymphoma.
- Molecular Pathogenesis and Target Characterization - Study of specific molecular abnormalities that are important in the pathogenesis of lymphoma with particular emphasis on abnormalities that may represent potential therapeutic targets.
- Clinical Investigations - Clinical trials in this area are based upon many observations made by the LRP investigators. Many lymphoma patients are referred to the Cancer Center for second opinions with LRP clinical investigators who are internationally respected.
Jennifer Black, Ph.D.
Michael Brattain, Ph.D.